[A clinical and experimental study of longatsef].
Data are reported of the results of clinical trials of the therapeutic efficacy of longaceph--a drug of the new generation of cephalosporins with a long period of half-decay--in acute pneumonia complicating influenza in 42 patients. The sensitivity of 120 microbial strains to longaceph was also studied. It was established that cephalosporin possesses a high efficacy in diseases caused by gram-positive and gram-negative microorganisms. A high degree of sensitivity to longaceph was observed in pneumococci biogenous and Streptococcus viridans, Staphylococcus aureus and epidermidis, klebsiellae and escherichiae. A new property of longaceph was found, namely, its capacity to stimulate the formation of endogenous interferon.